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Chikungunya virus (CHIKV) is a re-emerging alphavirus transmitted to humans by Aedes mosquitoes.
Since 2005, CHIKV has been spreading worldwide resulting in epidemics in Africa, the Indian Ocean
islands, Asia and more recently in the Americas. CHIKV is thus considered as a global health concern.
There is no speciﬁc vaccine or drug available for the treatment of this incapacitating viral infection. We
previously identiﬁed 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as selective inhibitors of CHIKV
replication and proposed the viral capping enzyme nsP1 as a target. This work describes the synthesis of
novel series of related compounds carrying at the aryl moiety a methylketone and related oximes
combined with an ethyl or an ethyl-mimic at 5-position of the triazolopyrimidinone. These compounds
have shown antiviral activity against different CHIKV isolates in the very low mM range based on both
virus yield reduction and virus-induced cell-killing inhibition assays. Moreover, these antivirals inhibit
the in vitro guanylylation of alphavirus nsP1, as determined by Western blot using an anti-cap antibody.
Thus, the data obtained seem to indicate that the anti-CHIKV activity might be related to the inhibition of
this crucial step in the viral RNA capping machinery.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chikungunya virus (CHIKV) is an alphavirus that is transmitted
to humans by Aedes mosquitoes, traditionally Aedes aegypti and
more recently also Aedes albopictus. CHIKV causes chikungunya
fever, a disease that is characterized by fever, nausea, headaches,
rash and a persistent arthralgia (Burt et al., 2012; Thiberville et al.,
2013). Although the clinical course is rarely associated with a fatal
outcome, the symptoms can be severe and disabling, and may last
for a long period of time (Couderc and Lecuit, 2015). In neonates,
elderly people or patients with underlying medical conditions such
as diabetes or heart disease, chikungunya fever can be associatedPerez).
rk.
r B.V. This is an open access articlewith severe complications, including death (Couderc and Lecuit,
2015; Thiberville et al., 2013). Of particular concern are patients
with a pre-existing arthritic disease that become infected by CHIKV
(Burt et al., 2014).
Since ﬁrst reported in 1952, CHIKV has been the cause of spo-
radic and infrequent outbreaks in Africa and Asia. In the last 10
years, the situation has dramatically changed and CHIKV is now
considered a re-emerging virus that is a global health threat
(Powers, 2015; Rougeron et al., 2015; Thiboutot et al., 2010). From
2004 onwards, CHIKV outbreaks have resulted in millions of cases
reported on the ﬁve continents. Phylogenetic tools are being used
to reconstruct the geographic spread of CHIKV outbreaks and to
characterize the circulating virus, a crucial issue for the prediction
and control of the CHIKV outbreak (Lo Presti et al., 2016; Weaver
and Forrester, 2015). As an example, since December 2013, with
the ﬁrst reported case in the Caribbean island of Saint Martin, theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Previously identiﬁed inhibitors of CHIKV replication based on [1,2,3]triazolo
[4,5-d]pyrimidin-7(6H)-ones and general structures of the compounds addressed
herein.
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Mediterranean Europe is also considered a potential area for CHIKV
expansion, and autochthonous cases have already been reported in
Italy and France (Delisle et al., 2015). Moreover, CHIKV infections
are considered to be underestimated since the clinical symptoms
and geographic distribution partially overlaps with dengue virus
infection (Lo Presti et al., 2016).
There are no speciﬁc drugs to prevent or cure CHIKV infections
(Abdelnabi et al., 2015; Ahola et al., 2015; Kaur and Chu, 2013;
Rashad et al., 2013). Treatment is primarily directed at relieving
the symptoms with over-the-counter drugs (Thiberville et al.,
2013). Taking the severe impact of this infection into account,
there is yet an unmet need for the discovery of compounds that are
able to effectively and selectively interfere with the replication of
CHIKV (Abdelnabi et al., 2015; Kaur and Chu, 2013). As the likeli-
hood to develop chronic CHIKV disease seems to be correlated with
the severity of symptoms during the acute phase of infection, a
potent antiviral administered during the acute infection may
diminish the chances to develop chronic disease (Abdelnabi et al.,
2017). However, it is not clear yet whether anti-CHIKV therapy
may be beneﬁcial on the development of chronic CHIKV-induced
arthritis. Compounds from natural origin such as ﬂavonoids (Lani
et al., 2016), known drugs such as niclosamide (Wang et al., 2016)
and suramine (Albulescu et al., 2015; Kuo et al., 2016) or synthetic
compounds (Ching et al., 2015; Mishra et al., 2016) have been
recently reported to inhibit CHIKV infection in cell-based assays.
Moreover, the alkaloid berberine has been shown to inhibit MAPK
signaling activated by CHIKV infection, leading to antiviral effects in
an animal model (Varghese et al., 2016).
In 2014, we discovered a series of small molecules that selec-
tively block CHIKV replication. We identiﬁed compound 1 (Fig. 1) as
an initial hit (Gigante et al., 2014). Structure-activity relationship
studies revealed that the [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one
structure and the meta-substituted aryl ring linked at position 3 of
the triazole were critical for anti-CHIKV activity. Accordingly, a
signiﬁcant improvement in terms of antiviral activity was observed
for compound 2, which has an ethyl substituent at position 5 of the
heterocyclic base (Fig. 1). In addition, we recently showed that
under the antiviral pressure of compound 1 drug resistant CHIKV
strains were selected that carried a P34S substitution in the non-
structural protein (nsP1). The importance of this mutation for the
resistance phenotype was conﬁrmed by reverse genetics (Delang
et al., 2016), demonstrating that the nonstructural protein 1
(nsP1) carrying the function for the mRNA capping is targeted by
our hit compound 1. Indeed, compound 1 inhibited the guanylyl-
transfer (GT) activity of the nsP1 of Venezuelan equine encephali-
tis virus (VEEV) that was used as the enzymatic model for the study
(Delang et al., 2016). In this study, we have now synthesized new
derivatives analogous to 1 carrying at the aryl moiety a methyl-
ketone and related oximes combined with an ethyl or an ethyl-
mimic at 5-position of the triazolopyrimidinone (Fig. 1). We have
determined their antiviral activity against CHIKV in virus-cell-
based assays, and the inhibition of the GT transfer by VEEV nsP1
for the most potent compounds.
2. Materials and methods
2.1. Chemistry procedures
Melting points were obtained on a Mettler Toledo M170 appa-
ratus and are uncorrected. The elemental analysis was performed
with a Heraus CHN-O-RAPID instrument. The elemental composi-
tions of the compounds agreed to within ±0.4 of the calculated
values. For all the tested compounds, satisfactory elemental anal-
ysis was obtained supporting greater than 95% purity. Electrospraymass spectra were measured on a quadrupole mass spectrometer
equipped with an electrospray source (Hewlett-Packard, LC/MS HP
1100). 1H and 13C NMR spectra were recorded on a Varian INNOVA-
300 operating at 300 MHz (1H) and 75 MHz (13C), respectively, and
a Varian INNOVA-400 operating at 400 MHz (1H) and 101 MHz
(13C), respectively.
Analytical TLC was performed on silica gel 60 F254 (Merck)
precoated plates (0.2 mm). Spots were detected under UV light
(254 nm) and/or charring with ninhydrin. Separations on silica gel
were performed by preparative centrifugal circular thin-layer
chromatography (CCTLC) on a ChromatotronR (Kiesegel 60 F254
gipshaltig (MercK)), with layer thicknesses of 1 and 2 mm and ﬂow
rates of 4 or 8 mL/min, respectively. Flash column chromatography
was performed with silica gel 60 (230e400 mesh) (Merck). Mi-
crowave reactions were performed using the Biotage Initiator 2.0
single-mode cavity instrument from Biotage (Uppsala). Experi-
ments were carried out in sealed microwave process vials utilizing
the standard absorbance level (400 W maximum power).
Detailed synthetic procedures and characterization of all the
compounds can be found in the Supplementary data.2.2. Virus strains and cells
Chikungunya virus (CHIKV) Indian Ocean strain 899 (Genbank
FJ959103.1) was generously provided by Prof. C. Drosten (University
of Bonn, Germany). Venezuelan equine encephalitis virus (VEEV)
vaccine strain TC83, CHIKV strain LR2006_OPY1 (Genbank
DQ443544.2) and the clinical isolates Venturini (Italy 2008), Congo
95 (2011) and St Martin (2013) were used in EPV in Marseille and
are freely disposable from the European Virus Archive (https://
www.european-virus-archive.com/). Sindbis virus (SINV, strain
HRsp, GenBank J02363.1) and the Semliki Forest virus (SFV, Viet-
nam strain, GenBank EU350586.1) belong to the collection of vi-
ruses at the Rega Institute of Medical Research, Belgium. All viruses
were propagated in African green monkey kidney cells [Vero cells
(ATCC CCL-81) or Vero E6 (ATCC CRL-1586)].
Vero cells were maintained in cell growth medium composed of
minimum essential medium (MEM Rega-3, Gibco, Belgium) sup-
plemented with 10% Foetal Bovine Serum (FBS, Integro, The
Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicarbonate
(Gibco). The antiviral assays were performed in the same medium
but supplementedwith 2% (instead of 10%) FBS. The E6 sub-clone of
Vero cells were maintained in Eagles MEM (Gibco) supplemented
with antibiotics, 1% glutamine, 1% non essential amino-acids
A. Gigante et al. / Antiviral Research 144 (2017) 216e222218(Gibco) and 7.5% FCS. Plating prior to infection and antiviral assays
were done in the same medium but with reduced serum concen-
tration (2.5%). All cell cultures were maintained at 37 C in an at-
mosphere of 5% CO2 and 95e99% humidity.
2.3. Antiviral assays
2.3.1. CPE-inhibition assay
Vero cells were seeded in 96-well tissue culture plates (Becton
Dickinson, Aalst, Belgium) at a density of 2.5  104 cells/well in
100 ml 2% FBS medium and were allowed to adhere overnight. Next,
a compound dilution series was prepared in the medium on top of
the cells (100 ml) after which the cultures were infected with 0.01
MOI of CHIKV 899 inoculum in 100 ml 2% FBS medium. The starting
concentration was 100 mg/ml for all compounds tested. A similar
setup was used for SINV and SFV. For SINV, a MOI of 0.001 was used
and for SFV, a MOI of 0.0001was used. Each assaywas performed in
3-fold in the same test and assays were repeated three times
independently to assess for inter-experiment variability. On day 5
post-infection (p.i.), the plates were processed using the MTS/PMS
method as described by the manufacturer (Promega, The
Netherlands). The 50% effective concentration (EC50), which is
deﬁned as the compound concentration that is required to inhibit
virus-induced cytopathic effect by 50%, was determined using
logarithmic interpolation.
2.3.2. Virus yield assay
The antiviral activity of the best compounds was validated in an
assay for CHIKV OPY 1, Venturini, Congo and St. Martin. The amount
of each virus in the assay has been calibrated by trial so that the
replication is at the beginning of the plateau at day 2 (multiplicity
of infection 3 103 for CHIK viruses and 3 104 for VEEV). One day
prior to infection, 5  104 Vero E6 cells were seeded in 100 ml of
medium (with 2.5% FCS) in each well of a 96-well titer plate. The
next day, two-fold serial dilutions of the compounds, in triplicates,
starting either at 10 mM, ﬁnal concentration, for CHIK Congo assay,
or 40 mM, for CHIKOPY, Venturini and VEEV, were added to the cells
(25 ml/well). Four Virus Control (VC) wells (per virus) were sup-
plemented with 25 ml medium containing 0.1% DMSO and four cell
control wells were supplemented with 50 ml of medium. Fifteen
minutes later, 25 ml of a virus mix containing the appropriate
amount of viral stock diluted in medium was added to the 96-well
plates. Cells were cultivated for 2 days after which 100 ml of the
supernatant was collected and transferred to 96 square well plates
preloaded with 400 ml of RAV-1 Lysis buffer from Macherey Nagel
“NucleoSpin 96 virus kit”. Viral RNAwas extracted on a Qiacube HT
automat using Cador Pathogen 96 HT kit (Qiagen), and quantiﬁed
by real time RT-PCR to quantify the amount of viral RNA, which is
representative for the amount of progeny virions that are produced
(SuperScript III Platinium one-step RT-PCR with Rox from Invi-
trogen). The four control wells were replaced by four 2-log di-
lutions of an appropriate T7-generated RNA standards. IC50 were
determined by ﬁtting a sigmoïdal curve on values of virus yield
inhibition (in %) versus the log values of drug concentration
(Kaleidagraph software).
2.4. Cytotoxicity assays
2.4.1. Cytotoxicity assay on vero cells
The cytotoxic and cytostatic effect of the compounds was eval-
uated in uninfected cells by means of the MTS/PMS method. Vero
cells were seeded in 96-well tissue culture plates (Becton Dick-
inson, Aalst, Belgium) at a density of 2.5  104 cells/well in 100 ml
2% FBS medium and were allowed to adhere overnight. Next, a
compound dilution series was prepared in the medium on top ofthe cells. Following 5 days of incubation, the plates were processed
using the MTS/PMS method as described by the manufacturer
(Promega, The Netherlands). The 50% cytostatic/cytotoxic concen-
tration (CC50; i.e. the concentration of compound that reduces the
overall metabolic activity of the cells by 50%) was calculated using
logarithmic interpolation. All assay wells were checked micro-
scopically for alterations of the cell or monolayer morphology.
2.4.2. Cytotoxicity on vero E6 cells
Cytotoxicities were assayed by measuring the cell viabilities in
the same culture settings along antiviral activities in parallel P96
wells plates. Two fold serial dilutions, starting 100 mM, in duplicates
or triplicates, were added in 25 mle100 ml of Vero E6 cells that have
been plated the day before. At day two, the medium was removed
and replaced by 70 ml of fresh medium containing 10 ml of CellTiter
blue reagent (Promega) and incubated for 90 min at 37 C. Cell
viabilities were measured as resoruﬁn ﬂuorescence readings on a
plate reader (Tecan Inﬁnite M200 Pro).
2.5. Inhibition assays of nsP1 guanylylation
VEEV nsP1 (strain P676, (GenBank accession number L04653.1)
amino acid 1 to 535) with a C-terminal 6-His tag was produced and
puriﬁed following a previously described protocol (Li et al., 2015).
The protein was quantiﬁed using UV absorbance at 280 nm, and
purity was checked on Coomassie blue stained SDS PAGE gel prior
the enzymatic assay. The VEEV nsP1 guanylylation reactions were
performed in 20 mL buffer containing 50 mM Tris (pH 7.0), 2 mM
MgCl2, 2 mM DTT, 10 mM m7GTP, 100 mM AdoHcy and 2 mM nsP1,
with an increasing concentrations of compounds (from 0 to 1 mM)
and incubated 1 h at 30 C. The guanylylation was detected by
Western Blot using an anti-m3G/m7G-cap monoclonal antibody
(Synaptic Systems) and quantiﬁed using ImageJ software (Delang
et al., 2016).
3. Results and discussion
3.1. Synthesis of new 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-
ones derivatives
Reaction of the ketone 1 with hydroxylamime hydrochloride or
methoxyamine hydrochloride in ethanol afforded the oximes 3 and
4 in 76 and 77% yields, respectively. Compound 4 kept signiﬁcant
anti-CHIKV activity, so the synthesis of the 5-ethyl analogues of the
ketone 1 and the methoxyamine 4 was addressed, as shown in
Scheme 1. The 3-azidophenylethanone 5 (Chakraborty et al., 2010)
reacted with methoxyamine hydrochloride under MW irradiation
to afford the methoxime 6 in 88% yield. Reaction of this azide with
cyanoacetamide in the presence of NaH in DMF afforded the 5-
aminotriazol 7 in 79% yield. Further reaction of 7 with ethyl pro-
pionate in dioxane in the presence of tBuOK under MW irradiation
afforded the triazolopyrimidine 8 in 72% yield. It should be
mentioned that, when the reaction between the aminotriazol 7 and
ethylpropionate was performed in the presence of EtONa in EtOH,
as described for the reaction of other aminocarboxamides with
esters (Miyashita et al., 1996), besides the cyclized product 8, a
signiﬁcant proportion of the Dimroth isomer of the staring material
was detected (Gigante et al., 2014). Hydrolysis of 8 under strong
acidic conditions provided the ketone derivative 9 with an ethyl at
position 5 of the base.
The results obtained in our previous series (Gigante et al., 2014)
have shown that substituents larger than an ethyl at position 5 of
the triazolopyrimidine resulted in a drop of the anti-CHIKV activity.
Here we have explored a subset of substitutions for which the steric
properties are similar to those of the ethyl group (Scheme 2). Thus,
a Reagents and conditions: (a) NH2OR, EtOH, MW, 80 ºC, 1 h (3, 76% yield and 4,77% yield).
Scheme 1. Synthesis of oxime derivatives on the methylketone 1.a Reagents and
conditions: (a) NH2OR, EtOH, MW, 80 C, 1 h (3, 76% yield and 4,77% yield).
A. Gigante et al. / Antiviral Research 144 (2017) 216e222 219reaction of the 5-amino-4-carboxamide 7 with N-Boc-Gly-OMe in
the presence of tBuOK followed by Boc removal by treatment with
TFA afforded the aminomethylen derivative 10 in 46% yield for the
two steps. On the other hand, reaction of 7with CS2 in the presence
of tBuOK afforded the 5-mercapto derivative 11 that was further
treated with methyl iodide at rt to provide the 5-methylthio de-
rivative 12 in 60% yield. Additionally, reaction of 12with MeNH2 in
MeOH under MW irradiation at 150 C afforded the 5-methylamino
derivative 13 in 38% yield.
Despite the interesting anti-CHIKV activity of the methoxime 8
(see Antiviral activity section), this compound exhibited poor water
solubility. In an effort to overcome this drawback, the incorporation
of different amines tethered to the oxygen of the oxime was envi-
sioned. This strategy has been described as a valuable approach to
improve water solubility in other oximes (Chen et al., 2011; Pergolaa Reagents and conditions: (a) NH2OCH3·HCl, EtO
cyanoacetamide, NaH 60%, DMF, 0 ºC to rt, 1 h (7, 
100 ºC, 1 h (8, 72% yield); (d) HCl 6N, dioxane, MW
OMe, tBuOK, THF, MW, 60 ºC, 2 h; ii) TFA, DCM, rt, 1
THF, MW, 120 ºC, 2 h, (11, 86% yield); (g) CH3I, DM
MeOH, DMF, MW, 150 ºC, 1 h, (13, 38% yield).
Scheme 2. Synthesis of the 5-Ethyl Triazolopyrimidin-7-ones 8e13.a Reagents and condition
60%, DMF, 0 C to rt, 1 h (7, 79% yield; (c) EtCO2Et, tBuOK, dioxane, MW, 100 C, 1 h (8, 72% y
THF, MW, 60 C, 2 h; ii) TFA, DCM, rt, 15 min, (10, 46% yield (two steps)); (f) CS2, tBuOK, THF, M
MeOH, DMF, MW, 150 C, 1 h, (13, 38% yield).et al., 2014; Vougogiannopoulou et al., 2008). In our case, an
ethylene linker was employed for the incorporation of a variety of
amines onto the oxime. Reaction of the methylketone 5
(Chakraborty et al., 2010) (Scheme 3) with hydroxylamine hydro-
chloride in ethanol under MW irradiation afforded the hydrox-
imino derivative 14 in 90% yield, that further reacted with 1,2-
dibromoethane in 10% NaOH/THF (1:1) in the presence of TBABr
to afford the bromo derivative 15 in an excellent yield. Reaction of
15with a variety of amines (methylpiperazine (a); morpholine (b);
thiomorpholine (c); diethylamine (d); cyclohexylamine (e); piper-
idine (f); pirrolidine (g) or 4-dimethylaminopiperidine (h), Scheme
3) in DMF and in the presence of NaI afforded compounds 16a-h in
good to excellent yields. The oximes were obtained as pure or
almost pure E isomers. Reaction of 16a-h with cyanoacetamide in
the presence of NaH in DMF led to the carboxamides 17a-h, that
were further treated with ethyl propionate in the presence of
tBuOK to yield the ﬁnal triazolopyrimidines 18a-h.3.2. Biological results
3.2.1. Evaluation of anti-CHIKV activity and cytotoxicity
The synthesized compounds were evaluated for their potential
to inhibit the CHIKV-induced cytopathogenic effect (CPE) in Vero
cells (Table 1). Dose-response curves for the most potent com-
pounds are provided as Supplementary Fig. S1. Chloroquine and our
previously reported hits (compounds 1 and 2) were included as
reference compounds. The antiviral activity is expressed as the 50%
effective concentration (EC50) and the 90% effective concentration
(EC90), indicating the concentration of compound required toH, MW, 80 ºC, 80 min (6, 88% yield); (b) 
79% yield; (c) EtCO2Et, tBuOK, dioxane, MW, 
, 120 ºC, 1 h (9, 33% yield); (e) i) N-Boc-Gly-
5 min, (10, 46% yield (two steps)); (f) CS2, tBuOK, 
F, rt, 30 min, (12, 60% yield); (h) CH3NH2 2N, 
s: (a) NH2OCH3$HCl, EtOH, MW, 80 C, 80 min (6, 88% yield); (b) cyanoacetamide, NaH
ield); (d) HCl 6N, dioxane, MW, 120 C, 1 h (9, 33% yield); (e) i) N-Boc-Gly-OMe, tBuOK,
W, 120 C, 2 h, (11, 86% yield); (g) CH3I, DMF, rt, 30 min, (12, 60% yield); (h) CH3NH2 2N,
a Reagents and conditions: (a) NH2OH·HCl, EtOH, MW, 80 ºC, 80 min (14, 90% yield); (b) Br(CH2)2Br, 
TBABr, NaOH 10% aq, THF/H2O, rt, 3 h (15, 90% yield); (c) Amine, NaI, DMF, 80 ºC, 3-16 h (71-98% 
yield); (d) Cyanoacetamide, NaH 60%, DMF, 0 ºC to rt, 1 h (66-90% yield); (e) EtCO2Et, tBuOK, dioxane, 
MW, 100 ºC, 1 h, (52-87% yield).
Scheme 3. Synthesis of the aminoalkyloximes 18a-h.a Reagents and conditions: (a) NH2OH$HCl, EtOH, MW, 80 C, 80 min (14, 90% yield); (b) Br(CH2)2Br, TBABr, NaOH 10% aq, THF/
H2O, rt, 3 h (15, 90% yield); (c) Amine, NaI, DMF, 80 C, 3e16 h (71e98% yield); (d) Cyanoacetamide, NaH 60%, DMF, 0 C to rt, 1 h (66e90% yield); (e) EtCO2Et, tBuOK, dioxane, MW,
100 C, 1 h, (52e87% yield).
Table 1
Antiviral evaluation of the triazolopyrimidines against CHIKV strain 899 in Vero
cells.
Compound EC50 (mM) ± SD a EC90 (mM) ± SD b CC50 (mM) ± SDc
1d 19 ± 2 38 ± 16 >743
2d 2.6 ± 1.0 8.8 ± 6.0 >668
3 69 ± 23 96 ± 36 >704
4 21 ± 9 92 ± 54 >670
8 3.6 ± 1.3 5.3 ± 0.9 101 ± 73
9 27 ± 13 >350 >1000
10 >549 >549 >549
11 >126 >126 >126
12 >24 >24 >24
13 26 ± 3 >160 >160
18a 58 ± 2 151 ± 77 380 ± 29
18b 12 ± 1 20 ± 1 >729
18c 5.2 ± 0.5 9.2 ± 2.7 162 ± 1
18d 16 ± 6 24 ± 9 165 ± 8
18e 135 ± 46 >236 383 ± 269
18f 6.9 ± 2 11 ± 4 95 ± 40
18g 16 ± 1.8 21 ± 1.8 166 ± 26
18h >424 >424 424 ± 32
Chloroquine 11 ± 7 21 ± 18 89 ± 28
All data are mean values ± standard deviation for at least three independent
experiments.
a 50% effective concentration or concentration required to protect 50% of the cells
against the cytopathic effect of the virus.
b 90% effective concentration or concentration required to protect 90% of the cells
against the cytopathic effect of the virus.
c 50% cytotoxic concentration.
d Data as reported in (Gigante et al., 2014).
Table 2
Antiviral evaluation of selected triazolopyrimidines against different laboratory
strains and clinical isolates of CHIKV, VEEV, SFV and SINV in Vero and Vero E6 cells.
Species Virus (strain) EC50 (mM) ± SD
8 18b 18f
CHIKV 899 (lab)a 3.6 ± 1.3 12 ± 1 6.9 ± 1.5
Venturini (Italy 2008)b 5.2 ± 0.2 6.7 9.6 ± 1.2
Venturini (Italy 2008)a 4.4 9.8
Congo 95 (2011)b 1.1 ± 0.1 2.5 3 ± 0.5
St. Martin 20235 (2013)b 4.2 ± 0.8 14 ± 3.5
VEEV TC83b ND ~22 >20
SINV HRsp (lab)a >101 >243 22 ± 3
SFV Vietnam (lab)a >101 >243 95 ± 40
VEEV: Venezuelan equine encephalitis virus; SINV: Sindbis virus; SFV: Semliki forest
virus; data shown are average values ± SD of at least two independent experiments.
CC50 values for 8, 18b and 18f on Vero cells are >300 mM, >100 mM and >100 mM,
respectively.
a EC50 value determined by CPE-inhibition assay.
b EC50 value determined by qRT-PCR.
A. Gigante et al. / Antiviral Research 144 (2017) 216e222220inhibit the virus-induced CPE by 50 and 90%, respectively. The ef-
fect of the compounds on non-infected cells is expressed as CC50,which corresponds to the calculated concentration of compound
that reduces the metabolic activity of compound-treated cells by
50%.
Compounds 3, 4, 8 and 9 resulted in signiﬁcant anti-CHIKV ac-
tivity at non-toxic concentrations. The best results were obtained
with the methoxyimino derivative 8 that showed an EC50 value of
3.6 ± 1.3 mM and an EC90 value of 5.3 ± 0.9 mM. However, when the
ethyl group at position 5 of the triazolopyrimidine in 8 was
replaced by a CH2NH2 (10), SH (11), or a SCH3 (12), the antiviral
activity was completely lost. The only exception in this subgroup
was compound 13 (X ¼ NHCH3) although it was at least 6-fold less
Table 3
Inhibition of VEEV nsP1 guanylylation as detected byWestern Blot using an anti-cap
antibody.
Compound IC50 (mM)a Compound IC50 (mM)
1 21 18d 16
2 10 18f <2
8 5.8 18g 3.2
18b 10
a The intensity of the signal was quantiﬁed using ImageJ software and the IC50
was deﬁned as the concentration of compound for which the intensity of the signal
is decreased by 50%. Gels of these experiments are shown in Supplementary Fig. S3.
A. Gigante et al. / Antiviral Research 144 (2017) 216e222 221active than 8. This pointed to an important role for the ethyl group
at position 5 of the triazolopyrimidine for the anti-CHIKV activity
not only in terms of steric properties, as previously reported
(Gigante et al., 2014), but also in terms of electronic properties
according to these data.
Most of the aminoalkyloximes 18a-h exerted signiﬁcant anti-
CHIKV activity with EC50 values in the range of 5e20 mM. Com-
pound 18c, with a thiomorpholine at the ethyl chain, and com-
pound 18f, with a piperidine substituent, had the best EC50 and
EC90 values in this series. Moreover, compound 18b with a distal
morpholine showed the best selectivity index (>60).
3.2.2. Antiviral activity against different CHIKV clinical isolates and
other alphaviruses
Compounds 8, 18b and 18f were evaluated for antiviral activity
against several CHIKV clinical isolates (Table 2) in Vero E6 cells
using virus yield reduction assays quantiﬁed by real-time RT-PCR
or virus-induced cell-killing measured by a cell viability assay
(dose-response curves are provided as Supplementary Fig. S2). The
three compounds showed antiviral activity against isolates ob-
tained from outbreaks in Italy (Venturini 2008), Africa (Congo
2011) and the Caribbean Americas (St Martin 2013) with EC50
values in the low mM range. It should be highlighted that they
were particularly active against the African Congo strain (i.e. EC50¼
1.1 ± 0.1 mM for 8). In addition, no cytotoxicity up to 100 mM was
observed in Vero E6 cells using the same experimental settings as
the antiviral assay. Because the antiviral assays were based on two
different methods in two laboratories, we therefore concluded
that these compounds were speciﬁc inhibitors of Chikungunya
virus replication.
These compounds did not provide signiﬁcant protection against
the replication of other alphaviruses with the only exception of
compound 18f that showed some activity against SINV and com-
pound 18b that resulted in modest antiviral activity against VEEV
(Table 2).
3.2.3. nsP1 evaluation
As mentioned in the introduction, we have recently reported
that compound 1 is able to inhibit the guanylation step catalyzed by
VEEV nsP1 (Delang et al., 2016), strongly suggesting that this
capping enzyme could be a target for this class of compounds.
Therefore it was important to determine the characteristics of the
new series of compounds in the guanylylation step catalyzed by
VEEV nsP1, as the recombinant CHIKV nsP1 does not display any
guanylylation activity in our assay (Li et al., 2015). The guanylyl-
transfer of mGTP on VEEV nsP1 was assessed in presence of
increasing concentrations of selected compounds and determined
by Western blot (see Supplementary Fig. S3). As shown in Table 3,
the oximes 8, 18b, 18d, 18f and 18g were able to inhibit the gua-
nylylation of VEEV nsP1 with IC50 values in the mM range. . Partic-
ularly relevant in this assay were compounds 8, 18f and 18g, with
IC50 values signiﬁcantly lower than that of the hit compound 1.However, it was quite surprising that despite inhibiting VEEV nsP1,
these compounds did not or only modestly show antiviral activity
against VEEV replication in cell culture.
Moreover, we have already shown (Delang et al., 2016) that
the amino acid at position 34 in VEEV nsP1 is relevant for the
inhibitory activity of these triazolopyrimidines. Recombinant
D34S VEEV nsP1 maintains the GT activity but the inhibitory
activity of the triazolopyrimidines, exempliﬁed by compound 2,
was signiﬁcantly alleviated. The N-terminal region of nsP1 where
the resistance mutation occurred is highly conserved and
although no structural model can be proposed, secondary struc-
tures and catalytic residues have been mapped and correspond to
common features to both VEEV and CHIKV nsP1 (Ahola and
Karlin, 2015). Thus, the folding of both nsP1 should be compa-
rable but to date there is no mean to assess local structural dif-
ferences. Therefore we cannot directly correlate the relative
differences between inhibition on VEEV nsP1 and CHIKV antiviral
effects. Still, the data here presented with the new series of
compounds are in agreement with those obtained for our original
hit 1, for which we presented evidences showing that nsP1 could
be the target.4. Conclusions
We previously reported on the identiﬁcation of 3-aryl-[1,2,3]
triazolo[4,5-d]pyrimidin-7(6H)-ones as selective anti-CHIKV
agents, exempliﬁed by compound 1, and further studied the
mechanism of action that involves the viral mRNA capping ma-
chinery through nsP1. Here we have addressed the synthesis and
evaluation of novel analogues within this series of compounds
thereby further dissecting the structural requirements for inhibi-
tion of CHIKV replication. The data obtained stress the exigent
structural requirements at position 5 of the triazolopyrimdine
portion so that both steric and electronic properties are very
important. On the other hand, the new synthesized oximes
(exempliﬁed by compounds 8, 18b or 18f) clearly show that the
functionalization of the methyl ketone at position 3 of the aryl ring
through oxime derivatization and incorporation of distal amines
improves the antiviral activity against CHIKV. The data obtained in
the nsP1 guanylylation assay provide also evidence that these ox-
imes are more potent inhibitors of the guanylylation step than the
initial hit 1. Further work is required to understand why the inhi-
bition of VEEV nsP1 is accompanied with no or only modest anti-
viral activity against VEEV in cell culture. Still, these
triazolopyrimidines represent, to the best of our knowledge, the
ﬁrst compounds able to inhibit the guanylylation reaction in
alphavirus mRNA capping.Author contributions
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